Tech Center 1600 • Art Units: 1641 1642
This examiner grants 38% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18030245 | NANOBODY-OGA FUSIONS AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 17573730 | ANTI-CD40 ANTIBODIES AND USES THEREOF | Non-Final OA | Emory University |
| 18559180 | COMPOSITIONS AND METHODS COMPRISING PROTEASE-ACTIVATED THERAPEUTIC AGENTS | Final Rejection | THE UNIVERSITY OF CHICAGO |
| 17754797 | METHODS AND COMPOSITIONS COMPRISING MODIFIED FAB SCAFFOLDS AND PROTEIN G FAB BINDING DOMAINS | Non-Final OA | The University of Chicago |
| 17631399 | METHODS AND COMPOSITIONS FOR INDUCING NOTCH SIGNALING IN TUMOR MICROENVIRONMENTS | Final Rejection | Fred Hutchinson Cancer Center |
| 18285304 | CHIMERIC ANTIGEN RECEPTOR THAT RECOGNIZES CCR8 AS ANTIGEN | Non-Final OA | Osaka University |
| 17693060 | ANTIGEN RECOGNIZING RECEPTORS TARGETING CD371 AND USES THEREOF | Non-Final OA | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES |
| 18255920 | COMBINATION THERAPY | Non-Final OA | ViiV Healthcare Company |
| 17165119 | TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT | Final Rejection | Seattle Children's Hospital (dba Seattle Children's Research Institute) |
| 18035123 | METHOD FOR PREPARING DENDRITIC CELL USING PLATELET LYSATE | Non-Final OA | KANAZAWA MEDICAL UNIVERSITY |
| 17598570 | CHIMERIC PROTEINS AND CHIMERIC PROTEIN COMPLEXES DIRECTED TO FMS-LIKE TYROSINE KINASE 3 (FLT3) | Final Rejection | Orionis Biosciences BV |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy